CD4 and neoplasm: In this flank tumor model, analysis of the peripheral blood at 2 weeks and 4 weeks post‐injection showed significantly higher numbers of overall CD3+ and CD4+ T‐cells in the GL261GIFT‐7 group compared to GL261vc (VC vs GIFT‐7 2 weeks: CD3+: 9.07% Vs 12.27% p < 0.05; 4 weeks: CD3+: 4.4% Vs 11.6% p < 0.0001; CD4+: 2.2% Vs 6.8% p < 0.001) (Figure 1a).